Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Galectin Therapeutics (NASDAQ:GALT) announced its quarterly earnings data on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04), Zacks reports.

Galectin Therapeutics Trading Up 4.3 %

NASDAQ:GALT traded up $0.09 during mid-day trading on Thursday, hitting $2.17. The company had a trading volume of 57,928 shares, compared to its average volume of 150,842. The firm has a market capitalization of $134.86 million, a price-to-earnings ratio of -2.96 and a beta of 0.63. Galectin Therapeutics has a 1 year low of $1.55 and a 1 year high of $4.27. The business has a fifty day simple moving average of $2.36 and a 200-day simple moving average of $2.53.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 18th.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.